Navigation Links
Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting
Date:4/14/2009

-- Phase 1 Data from Colorectal Cancer and Oral Picoplatin Trials To Be Presented --

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present final data from two Phase 1 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the American Association for Cancer Research 100th Annual Meeting 2009 at the Colorado Convention Center in Denver. The Company will present efficacy and safety data from its Phase 1 trial of picoplatin in colorectal cancer (CRC) and bioavailability data from its Phase 1 trial of an oral formulation of picoplatin.

    Details are as follows:

    A Phase 1 study of picoplatin in combination with 5-fluorouracil and
    leucovorin (FOLPI) for colorectal cancer (CRC): Comparison of two
    picoplatin schedules
    Abstract #3578
    Earhart R, Gladkov OA, Cheporov SV, Biakhov MY, Manikhas B, Berdov B,
    Tjulandin S, Breitz H, De Jager R.
    Tuesday, April 21, 8:00 a.m. MDT
    Clinical Research 11 Session
    Hall B-F, Poster Section 30

    A Phase 1 randomized crossover oral picoplatin bioavailability
    pharmacokinetics and pharmacodynamics study
    Abstract #3594
    Phillips A, Saleh M, Yee L, Sharma S, Houston S, Karlin D, Breitz H,
    DeJager R, Earhart R.
    Tuesday, April 21, 8:00 a.m. MDT
    Clinical Research 12
    Hall B-F, Poster Section 31

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic 2 colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit

http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... ... cuvettes are used in leading laboratories all over the globe. Their cute firefly ... addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle ... plating options designed to address fractures of the distal tibia and fibula. This ... Acumed Ankle Plating System 3 is composed of seven plate families that span ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):